These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19775997)

  • 21. Lessons Learned from Two Decades of Anticancer Drugs.
    Liu Z; Delavan B; Roberts R; Tong W
    Trends Pharmacol Sci; 2017 Oct; 38(10):852-872. PubMed ID: 28709554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers in early cancer drug development: limited utility.
    Glassman RH; Ratain MJ
    Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
    Cadete A; Alonso MJ
    Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
    Saijo N
    Cancer Treat Rev; 2012 Feb; 38(1):63-7. PubMed ID: 21652149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exosomes: Diagnostic Biomarkers and Therapeutic Delivery Vehicles for Cancer.
    Jiang L; Gu Y; Du Y; Liu J
    Mol Pharm; 2019 Aug; 16(8):3333-3349. PubMed ID: 31241965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer chemoprevention: progress and promise.
    Kelloff GJ; Sigman CC; Greenwald P
    Eur J Cancer; 1999 Dec; 35(14):2031-8. PubMed ID: 10711244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.
    Venkatakrishnan K; Ecsedy JA
    Clin Pharmacol Ther; 2017 Jan; 101(1):99-113. PubMed ID: 27804123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translational study in cancer research.
    Saijo N
    Intern Med; 2002 Oct; 41(10):770-3. PubMed ID: 12412993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box.
    Marchiò C; Dowsett M; Reis-Filho JS
    BMC Med; 2011 Apr; 9():41. PubMed ID: 21504565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selecting the best drugs for phase I clinical development and beyond.
    Loong HH; Siu LL
    Am Soc Clin Oncol Educ Book; 2013; ():469-73. PubMed ID: 23714572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review: new biological insights in early clinical studies.
    Maur M; Sessa C
    Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.
    Packianathan S; Mehta RG; Mehta RR; Hall WH; Boerner PS; Beckett LA; Vijayakumar S
    Cancer J; 2004; 10(6):357-67. PubMed ID: 15701267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug development in oncology: classical cytotoxics and molecularly targeted agents.
    Kummar S; Gutierrez M; Doroshow JH; Murgo AJ
    Br J Clin Pharmacol; 2006 Jul; 62(1):15-26. PubMed ID: 16842375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Side effects of anticancer treatment and the needs for translational research on toxicity: a clinician's perspective].
    Shimizu C
    Nihon Yakurigaku Zasshi; 2015 Aug; 146(2):72-5. PubMed ID: 26256743
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeted therapies; who detects the target?
    Meijer GA; Oudejans JJ
    Cell Oncol; 2005; 27(3):165-7. PubMed ID: 16037636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.